Select language:
On this page


    Prescription under medical supervision


    Therapeutic action

    • Antimalarial


    • Intermittent preventive treatment of malaria in pregnancy (IPTp-SP), as of the second trimester, in areas with moderate to high malaria transmission in Africa

    Forms and strengths

    • Sulfadoxine 500 mg/pyrimethamine 25 mg co-formulated tablet

    Dosage and duration

    • 3 tablets single dose for each treatment, starting as early as possible in the second trimester
    • Each treatment should be given at least one month apart and at least 3 doses should be given during pregnancy.

    Contra-indications, adverse effects, precautions

    • Do not administer to patients with allergy to sulfonamides.
    • Do not administer to HIV-infected women taking co-trimoxazole prophylaxis.
    • May cause: gastrointestinal disturbances, skin reactions, sometimes severe (toxic epidermal necrolysis and Stevens-Johnson syndrome); anaemia, leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia in patients with G6PD deficiency.
    • Do not use in combination with co-trimoxazole.
    • Do not give folic acid on the same day SP is administered, or within 2 weeks thereafter.
    • Pregnancy: CONTRA-INDICATED during the first trimester (risk of neural tube defects)


    • Also comes as co-packaged dispersible tablets for seasonal malaria chemoprevention in children: amodiaquine 153 mg + sulfadoxine/pyrimethamine 500 mg/25 mg and amodiaquine 76.5 mg + sulfadoxine/pyrimethamine 250 mg/12.5mg.


    – Below 25 °C